The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

New study shows intermittent HT as effective as continuous HT

vartabebo
vartabebo CSN Member Posts: 10
in Prostate Cancer #1
This report was apparently published today at the annual meeting of the American Society of Clinical Oncology...

http://www.medicalnewstoday.com/releases/227668.php
Like Care

Comments

  • VascodaGama
    VascodaGama CSN Member Posts: 3,788 Member
    #2
    NCCN may alter their guidelines
    Arthur

    Great news. These findings will influence the importance given to the newer drugs as well (such as Abiraterone acetate), which do not make part of the protocols of the patients/cases used in the trials but have proven effectiveness with lesser side effects.
    I hope institutions like NCCN will alter their guidelines and introduce newer measures regarding HT, based on truthful results like these.

    Here is the abstract of the trials;
    http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775

    Thanks for posting the article.

    VG
    Like Care

Discussion Boards